Intercytex Ltd.
http://www.intercytex.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intercytex Ltd.
STOCKWATCH: How to hide the meaning of clinical data
Investors like to be informed. So it is more than a little frustrating when public companies' clinical trial announcements omit important details; the way the trial was conducted, for instance, or the type of statistical analysis or the nature of the control with which a treatment was compared (scripintelligence.com, 16 July 2013).
Biologics: The Growth Engine In Advanced Wound Care
With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat. This article is reprinted from the June issue of Medtech Insight.
Biologics: The Growth Engine in Advanced Wound Care
With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat.
Biotech funding in a cold climate
Yesterday was the 92nd anniversary of the signing of the armistice that brought the hostilities of the First World War formally to an end. Coincidentally, it also marked the re-emergence of the UK-based regenerative medicine company Intercytex, which announced that its lead product, the cell therapy Vavelta, is to be evaluated by the US military to help treat injured soldiers.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Regenerative Medicine Assets Limited (formerly Intercytex Group plc)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice